Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRINOX vs FLOT in Resectable Gastric Cancer
NCT04393584Phase 3Recruiting
- Sponsor
- N.N. Blokhin Russian Cancer Research Center
- Start
- Jan 2019
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of irinotecan in gastric adenocarcinoma, esophagogastric junction adenocarcinoma (GEJA), sponsored by N.N. Blokhin Russian Cancer Research Center. Started Jan 2019; status: recruiting.
02
Drugs
irinotecan
03
Conditions
gastric adenocarcinomaesophagogastric junction adenocarcinoma (GEJA)
Beyond the preview
Go deeper on NCT04393584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04393584.